Infinity Announces Third Quarter 2009 Results Conference Call

Infinity Announces Third Quarter 2009 Results Conference Call - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-lef...
Click here to read the whole Article (external link)

Q3 2009 Infinity Pharmaceuticals, Inc. Earnings Release - Time Not Supplied

Earnings Announcements for Monday, November 9CompanySymbolTimeConferenceCall4Kids EntertainmentKDEBefore Market OpenAbatixABIX.PKAfter Market CloseAbraxas PetroleumAXASAfter Market CloseListenACADIA PHARMACEUTICALS INCACADAfter Market CloseADVANCED BATTERY TECHNOLOG INCABATAfter Market CloseAdvanced PhotonixAPIAfter Market CloseListenAdvanta CorporationADVNATime Not SuppliedAdvocatAVCAAfter Market CloseListenAlbany Molecular ResearchAMRIBefore Market OpenAlesco Financial Inc.AFNAfter Market CloseAlexza Pharmaceuticals Inc.ALXAAfter Market CloseListenAlliance One International, Inc.AOIAfter Market CloseAllianz SEAZSEY.PK01:30 am ETListenALLION HEALTHCARE INCALLITime Not SuppliedALPHATEC HOLDINGS INCATECTime Not SuppliedAmerican CareSource Holdings, Inc.ANCIAfter Market CloseA...
Click here to read the whole Article (external link)

Infinity Reports Recent R&D Highlights and Third Quarter 2009 Results

-- Enrollment Open in All of Infinity's Ongoing Hsp90 Chaperone Inhibitor Studies -- Infinity Maintains Financial Strength to Advance Its Innovative Product Pipeline CAMBRIDGE, Mass., Nov. 9, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI - News), an innovative cancer drug discovery and development company, today reviewed recent R&D highlights and announced third quarter 2009 financial results. "During the past quarter, we have advanced our clinical and preclinical programs and strengthened our operational capabilities, activities necessary to achieve our mission of sustainably discovering, developing and delivering to patients meaningful new medicines," said Adelene Q. Perkins, president and chief business officer, Infinity. "We are in the distinctive position of having the cash resources and committed capital to enable us to invest aggressively in the advancement of our pipeline of innovative anti-cancer programs to achieve key clinical inflection points." Hsp90 Chaperone Inhibitor Program Highlights Infinity is making progress in the clinical evaluation of its family of heat shock protein 90 (Hsp90) chaperone inhibitors in multiple cancer indications. Infinity's inhibitors include IPI-504 (retaspimycin hydrochloride) and orally administered IPI-493. In the third quarter, Infinity received approval of protocol amendments for its studies of IPI-504, which included dose and schedule modifications. Patient enrollment is ongoing in all stud...
Click here to read the whole Article (external link)

Infinity to Present at Upcoming Conferences

Infinity to Present at Upcoming Conferences - Yahoo! Finance.gnwlistitemmarginbottom {margin-bottom: 10.0px} .gnwtablebottommargin {margin-bottom: 10.0px} .gnwcellpaddingleft0 {padding-left: 0.0px} .gnwverticalaligntop {vertical-align: top} .gnwtextaligncenter {text-align: center} .gnwcellparagraphmargin {margin-bottom: 0px; margin-top: 0px} .gnwverticalalignbottom {vertical-align: bottom} .gnwwhitespacenowrap {white-space: nowrap} .gnwtextalignright {text-align: right} .gnwcellpaddingright0 {padding-right: 0.0px} .gnwunderlinestyle {text-decoration: underline} .gnwtextalignleft {text-align: left} .gnw_heading {font: 16px Arial; text-align: center} .gnw_subhead {font: 12px Arial; text-align: center} .gnw_colhead {font: 12px Arial; text-align: center} .gnw_colhead_uline {font: 12px Arial; text-align: center; border-bottom: solid black 1.0pt;} .gnw_colhead_dline {font: 12px Arial; text-align: center; border-bottom: double black 2.5pt;} .gnw_label {font: 12px Arial; vertical-align: bottom; text-align: left } .gnw_label_uline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: solid black 1.0pt;} .gnw_label_uline_i10 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i15 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i20 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i25 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_uline_i30 {font: 12px Arial; vertical-align: bottom; text-align: right; border-bottom: solid black 1.0pt;} .gnw_label_dline {font: 12px Arial; vertical-align: bottom; text-align: left; border-bottom: double black 2.5pt;} .gnw_label_i10 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 10.0px;} .gnw_label_i15 {font: 12px Arial; vertical-align: bottom; text-align: left; padding-left: 15.0px;} .gnw_l...
Click here to read the whole Article (external link)

INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statement

Show all filings for INFINITY PHARMACEUTICALS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for INFINITY PHARMACEUTICALS, INC. 9-Nov-2009Results of Operations and Financial Condition, Financial Statement Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All inform...
Click here to read the whole Article (external link)

Infinity Pharma 3Q loss narrows on payments

Copyright © 2009 Yahoo! All rights reserved. Privacy Policy - Terms of Service - Copyright Policy - Report Problems Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quote data delayed 15 minutes for Nasdaq, NYSE and Amex. Real-Time continuous streaming quotes are available through our premium service. You may turn streaming quotes on or off. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Yahoo! is not an investment adviser and does not provide, endorse or review any information or data contained herein....
Click here to read the whole Article (external link)

Adelene Q. Perkins Named "Best Executive" at Annual Stevie(R) Awards Ceremony

CAMBRIDGE, Mass., Nov. 16, 2009 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI - News), an innovative cancer drug discovery and development company, today announced that Adelene Q. Perkins, president and chief business officer, was named the 2009 "Best Executive: Non-Services Business" in the 6th Annual Stevie Awards for Women in Business, presented at the Annual Award Dinner and Ceremony held on November 13, 2009 in New York City. Ms. Perkins was selected from more than 1,100 nominees across several categories at this international award competition. A board of 50 judges and advisors from around the world selected the Stevie Award Winners from among the finalists. Ms. Perkins was recognized as "Best Executive" for non-service organizations with up to 2,500 employees. In 2008, Ms. Perkins was a finalist for the "Lifetime Achievement Award" in the Annual Stevie Awards for Women. "I am humbled to receive this recognition alongside so many respected and impactful business leaders," said Ms. Perkins. "I accept the award on behalf of all of Infinity's Citizen-Owners. Without such an exceptional team, and the support of my family, this award would not have been possible; I am grateful for all of them." Ms. Perkins has more than 25 years of general management experience in the healthcare, pharmaceutical, and biotechnology industries. She joined Infinity early in its history, and has been an integral figure in establishing Infinity's strategic plan and leading the company through signif...
Click here to read the whole Article (external link)

INFINITY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits

Show all filings for INFINITY PHARMACEUTICALS, INC. | Request a Trial to NEW EDGAR Online Pro Form 8-K for INFINITY PHARMACEUTICALS, INC. 16-Nov-2009Regulation FD Disclosure, Financial Statements and Exhibits Copyright © 2009 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service - Copyright/IP Policy - Send Feedback SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information ...
Click here to read the whole Article (external link)

INFINITY PHARMACEUTICALS, INC. Financials

PERIOD ENDING30-Sep-0930-Jun-0931-Mar-0931-Dec-08Total Revenue13,776  13,165  9,429  67,049  Cost of Revenue -   -   -   -  Gross Profit13,776  13,165  9,429  67,049  Operating ExpensesResearch Development18,499  20,713  21,242  16,437  Selling General and Administrative4,570  5,681  5,330  5,602  Non Recurring -   -   -   -  Others -   -   -   -  Total Operating Expenses -   -   -   -  Operating Income or Loss(9,294)(13,229)(17,143)45,010  Income from Continuing OperationsTotal Other Income/Expenses Net401  2,337  13,192  1,764  Earnings Before Interest And Taxes(8,892)(10,892)(3,950)46,773  Interest Expense433  433  0  2  Income Before Tax(9,326)(11,325)(3,950)46,772  Income Tax Expense -   -   -   -  Minority Interest -   -   -   -  Net Income From Continuing Ops(9,326)(11,325)(3,950)46,772  Non-recurring EventsDiscontinued Operations -   -   -   -  Extraordinary Items -   -   -   -  Effect Of Accounting Changes - &...
Click here to read the whole Article (external link)